Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jacqueline Ritter

Physician Assistant Trenton, NJ Physician Assistant

NPI 1376705996 CMS profile 10680268

1700 Nottingham Way, Trenton, NJ 08619

Open in the dashboard

General payments

$1,446

95 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacqueline Ritter of Trenton, NJ is reported in the CMS Open Payments database as having received $1,446 across 95 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $58 3
2024 General $264 15
2023 General $459 31
2022 General $439 31
2021 General $226 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacqueline Ritter
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jacqueline Ritter were reported at $58. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jacqueline Ritter Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $226 $132 $37–$438 $132
2022 $439 $155 $48–$522 $149
2023 $459 $167 $52–$557 $160
2024 $264 $178 $55–$600 $164
2025 $58 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $514 35 payments
  2. Pfizer Inc. $211 14 payments
  3. Lilly USA, LLC $117 8 payments
  4. Exact Sciences Corporation $94 5 payments
  5. Merck Sharp & Dohme Corporation $82 6 payments
  6. Abbott Laboratories $77 4 payments
  7. Amgen Inc. $71 5 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $66 4 payments
  9. AstraZeneca Pharmaceuticals LP $42 3 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $35 2 payments
  11. Other $138 9 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,446 95 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $418 29 payments
  2. Ozempic $400 28 payments
  3. PREVNAR 20 $150 10 payments
  4. COMIRNATY $108 7 payments
  5. PREVNAR 13 $97 7 payments
  6. PAXLOVID $79 5 payments
  7. Otezla $71 5 payments
  8. Repatha $71 5 payments
  9. Cologuard Collection Kit $70 4 payments
  10. STEGLATRO $68 5 payments
  11. Other $893 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 89 drugs

Part D claims

3,640

Median for Physician Assistant: 241

Drug cost

$180,839

Median for Physician Assistant: $4,110

Branded share of claims

14.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 21 $32,614
Eliquis Apixaban Brand 30 $31,263
Linzess Linaclotide Brand 18 $24,991
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 18 $20,493
Januvia Sitagliptin Phosphate Brand 18 $15,917
Celecoxib Generic 23 $2,966
Rosuvastatin Calcium Generic 142 $2,832
Singulair Montelukast Sodium Brand 11 $2,803
Levothyroxine Sodium Generic 195 $2,489
Synthroid Levothyroxine Sodium Brand 22 $2,477

The 10 drugs with the highest cost, of 89 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$33,587

Of which drugs: $5,064

Medicare patients

163

Average age 73

Services billed

471

107 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Diabetes 29%
Ischemic heart disease 27%
Chronic kidney disease 20%
Cancer 18%
Depression 16%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 23 23 $1,882

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $25
$25 — —
Ozempic
  • Novo Nordisk Inc $25
$25 — —
JARDIANCE
  • Lilly USA, LLC $18
$18 21 —
SHINGRIX
  • GlaxoSmithKline, LLC. $18
$18 — —
Wegovy
  • Novo Nordisk Inc $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record